The rationale for applying trastuzumab in patients with advanced pancreatic cancer is based on studies in which 11% of human specimens overexpressed HER2 with a score of 3 and 26% with a score of 2 [16,17]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.